1. Home
  2. IDYA vs MTRN Comparison

IDYA vs MTRN Comparison

Compare IDYA & MTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$27.99

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo Materion Corporation

MTRN

Materion Corporation

HOLD

Current Price

$205.30

Market Cap

2.6B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
MTRN
Founded
2015
1931
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.6B
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
IDYA
MTRN
Price
$27.99
$205.30
Analyst Decision
Strong Buy
Buy
Analyst Count
16
4
Target Price
$52.86
$52.50
AVG Volume (30 Days)
1.4M
222.0K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
N/A
0.32%
EPS Growth
61.90
1178.57
EPS
N/A
0.92
Revenue
$218,710,000.00
N/A
Revenue This Year
N/A
$15.31
Revenue Next Year
$201.05
$7.57
P/E Ratio
N/A
$218.55
Revenue Growth
3024.43
N/A
52 Week Low
$17.17
$73.61
52 Week High
$39.28
$204.83

Technical Indicators

Market Signals
Indicator
IDYA
MTRN
Relative Strength Index (RSI) 36.30 72.58
Support Level $26.05 $113.78
Resistance Level $28.05 N/A
Average True Range (ATR) 1.15 8.85
MACD -0.12 1.26
Stochastic Oscillator 7.68 99.65

Price Performance

Historical Comparison
IDYA
MTRN

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About MTRN Materion Corporation

Materion Corp specializes in the development of specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings. The company operates in four reportable segments: Performance Materials, Electronic Materials, Precision Optics, and Others. The majority of revenue is derived from Electronic Materials which produces chemicals, microelectronics packaging, precious metal, non-precious metal, and specialty metal products, including vapor deposition targets, frame lid assemblies, clad and precious metal pre-forms. The Performance Materials segment provides engineered solutions comprised of beryllium and non-beryllium-containing alloy systems and custom-engineered parts.

Share on Social Networks: